Deloitte has released a report highlighting successful cancer drug development approaches that could help the biotech and healthcare IT world in the future.
The report, titled “Innovative Strategies for Oncology Drug Development,” benchmarks 150 biotech companies and how they leveraged FDA and other regulatory benefits to their advantage.
“Scientific innovation has brought measurable rewards such as reduced development times, higher success rates for cancer drugs, and increased investment and activity across the biopharmaceutical industry,” said Lisa Natanson, senior analyst, Deloitte Recap LLC. “We see clear patterns of successful drug development from this study of a defined set of biotechnology companies that have produced innovative cancer drugs in the last decade.”
Follow me on Facebook